Dr. Reddy’s Laboratories Ltd (NYSE:RDY – Get Free Report)’s stock price hit a new 52-week low during trading on Wednesday following a dissappointing earnings announcement. The stock traded as low as $12.19 and last traded at $11.9350, with a volume of 5648 shares. The stock had previously closed at $12.56.
The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The business had revenue of $850.26 million for the quarter, compared to analysts’ expectations of $850.56 million. Dr. Reddy’s Laboratories had a return on equity of 9.48% and a net margin of 10.15%.
Key Stories Impacting Dr. Reddy’s Laboratories
Here are the key news stories impacting Dr. Reddy’s Laboratories this week:
- Negative Sentiment: Dr. Reddy’s fiscal first-quarter earnings and revenue came in below estimates, with weaker North America generics sales weighing on results and contributing to the selloff. Dr. Reddy’s Q1 Earnings and Revenues Miss Estimates, Stock Down
- Negative Sentiment: Reuters reported that quarterly profit slumped more than expected, as muted sales of a key generic oncology drug and pricing pressure in the U.S. market hurt profitability. Indian drugmaker Dr Reddy’s posts quarterly profit slump
- Negative Sentiment: Investor sentiment was also hurt by reports of a semaglutide setback and concerns that potential U.S. tariff threats could add further pressure to future earnings. Why Dr. Reddy’s sank: Profit plunge, semaglutide setback and Trump’s tariff threat
Analyst Ratings Changes
Check Out Our Latest Report on RDY
Hedge Funds Weigh In On Dr. Reddy’s Laboratories
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its position in shares of Dr. Reddy’s Laboratories by 7.6% in the second quarter. Invesco Ltd. now owns 253,342 shares of the company’s stock valued at $3,808,000 after acquiring an additional 17,907 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Dr. Reddy’s Laboratories by 71.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock worth $47,000 after purchasing an additional 1,294 shares during the period. First Trust Advisors LP boosted its holdings in Dr. Reddy’s Laboratories by 23.3% in the 2nd quarter. First Trust Advisors LP now owns 65,652 shares of the company’s stock worth $987,000 after acquiring an additional 12,390 shares during the period. Sei Investments Co. boosted its position in Dr. Reddy’s Laboratories by 37.3% in the 2nd quarter. Sei Investments Co. now owns 124,136 shares of the company’s stock valued at $1,866,000 after buying an additional 33,747 shares during the last quarter. Finally, Quantinno Capital Management LP grew its stake in Dr. Reddy’s Laboratories by 92.6% during the 2nd quarter. Quantinno Capital Management LP now owns 235,044 shares of the company’s stock valued at $3,533,000 after purchasing an additional 112,988 shares in the last quarter. Institutional investors and hedge funds own 3.85% of the company’s stock.
Dr. Reddy’s Laboratories Stock Performance
The company has a market capitalization of $9.87 billion, a price-to-earnings ratio of 26.88, a price-to-earnings-growth ratio of 1.75 and a beta of 0.25. The company’s fifty day simple moving average is $13.53 and its two-hundred day simple moving average is $13.65. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.34 and a current ratio of 1.80.
Dr. Reddy’s Laboratories Company Profile
Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.
The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.
Featured Stories
- Five stocks we like better than Dr. Reddy’s Laboratories
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
